Earnings Release2026-04-20
IVL3003 Trial
인벤티
인벤티지랩
389470
Signal Score
50C — Neutral
Score50 / 100
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2406
Risk-adjusted indicator based on 2406 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Total subjects enrolled: 73
- • Dose levels: 60 mg, 120 mg, 240 mg
3 more figures — unlock with API access
AI Analysis Summary
Developer & Pro plans
Risk Factors
Developer & Pro plans
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Historical pattern data via REST API
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.
AI-processed analysis. Based on: 투자판단관련주요경영사항(임상시험결과) (건강한 성인을 대상으로 IVL3003의 피하 또는 근육 주사와 ARICEPT®(도네페질) 정제 반복 투여 간 비교를 위한 공개, 탐색적, 연속적, 약동학, 단일용량상승 1상 임상시험). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.